MGX Metagenomi Inc. Company Future Sales Volume

Brandmark of Metagenomi, Inc (MGX)

Leadership in precision genome editing is driving growth, as evidenced by the planned sales levels of Metagenomi, Inc. (MGX), where the figure stands at 0.01. The business foundation is based on the ownership of unique enzymes for therapy. Sustainability is ensured through adherence to bioethics and eco-friendly production. This chart demonstrates capitalization potential driven by exclusive contracts with major pharmaceutical behemoths.

MGX - Metagenomi, Inc. Company Future Sales over the range 02/21/2024 - 11/18/2026

Metric breakdowns and analytics for Metagenomi, Inc. (MGX)

- stock quotes and analyst forecast:
Basic company analysis:MGX Metagenomi Inc.
Brand item of Metagenomi Therapeutics

For Metagenomi, Inc., whose revenues depend on partnership agreements rather than market pricing, this indicator reveals hidden revenue trends. The calculation model filters out one-time payments, converting sporadic reporting into a continuous data stream. By analyzing the company's prospective sales volume, an investor can see the real expansion dynamics of the biotech platform. The upward trend confirms the demand for DNA editing technologies; however, excessive values signal a risk of asset overvaluation.

Competitors of Metagenomi, Inc.

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume